Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01251354 · ClinicalTrials.gov registry record · Phase 2
Study of BN83495 in Post-menopausal Women With Endometrial Cancer Post-chemotherapy
A Phase 2 study, sponsored by Ipsen.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT01251354 is a Phase 2 study that was terminated before completion, run by Ipsen. The registered enrollment target is 6 participants.
The verdict
NCT01251354, a Phase 2 study, was terminated before completion, sponsored by Ipsen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of the protocol is to determine the effect of BN83495 on the progression of endometrial cancer with estrogen receptor in post menopausal women who had previously received chemotherapy.
Interventions
- DRUG BN83495
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2010-11 |
| Est. Completion | 2011-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01251354
The ClinicalTrials.gov registry entry for NCT01251354 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ipsen, which has 85 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BN83495 is the first listed.
NCT01251354 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01251354 about?
NCT01251354 is a clinical study titled "Study of BN83495 in Post-menopausal Women With Endometrial Cancer Post-chemotherapy". The purpose of the protocol is to determine the effect of BN83495 on the progression of endometrial cancer with estrogen receptor in post menopausal women who had previously received chemotherapy.
What is the current status of trial NCT01251354?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2010-11. Estimated completion is 2011-07.
What interventions are being tested in trial NCT01251354?
The interventions under investigation include: BN83495 (DRUG).
Who is sponsoring clinical trial NCT01251354?
This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.